Valneva trims R&D footprint by shutting French facility
Not long after cutting its sales forecast for 2025, Valneva has decided to decrease its operational footprint in France by…
27 Nov 2025
SK bolsters oncology pipeline in radiopharmaceutical licensing deal
SK Biopharmaceuticals has in-licensed its second radiopharmaceutical – this time from a US-based academic organisation – in a bid to enhance its oncology pipeline. Through its deal with the Wisconsin…
27 Nov 2025
BeOne’s sonrotoclax gains priority FDA review for mantle cell lymphoma
The US Food and Drug Administration (FDA) has accepted the new drug application (NDA) for BeOne Medicines’ B-cell lymphoma 2 (BCL2) inhibitor, sonrotoclax, and granted it priority review for use…
27 Nov 2025
Corstasis Therapeutics partners CVL for Enbumyst integration
Corstasis Therapeutics has announced a collaboration with Cardiovascular Logistics (CVL) to advance the adoption and integration of Enbumyst nasal spray into heart failure care. The approach is consistent with outpatient…
26 Nov 2025
Reeves’ Autumn Budget targets community health centres and NHS tech outlay
During the UK’s Autumn Budget, Rachel Reeves has unveiled further technology investments for the UK’s National Health Service (NHS) and, separately, the establishment of 250 neighbourhood healthcare centres. Reeves, Chancellor…
26 Nov 2025
Dupixent gains chronic spontaneous urticaria indication in Europe
Regeneron and Sanofi’s Dupixent (dupilumab) has gained approval to treat chronic spontaneous urticaria (CSU) in Europe, adding yet another indication to the blockbuster anti-inflammatory drug. The European Commission’s (EC) decision to…
26 Nov 2025
Questions on how new IRA drug prices will affect MFN agreements
As the US Centers for Medicare and Medicaid Services (CMS) has released the new prices for 15 drugs that have been added to the Inflation Reduction Act (IRA) an expert questions…